LONDON, UK / ACCESSWIRE / May 15, 2019 / Hemogenyx Pharmaceuticals plc ('Hemogenyx' or the 'Company') (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that it has come to the Company's attention that it has not been able to issue warrants to all Qualifying Shareholders under the terms of the Warrant Instrument dated 8 September 2017. This may be the case particularly for shares held through nominee companies. As a result, the Company's board of directors has resolved to vary the terms of the Warrant Instrument to impose a new final deadline for the submission of claims for warrants, together with satisfactory supporting evidence, of Friday 14 June 2019. No further extension beyond this deadline will be granted and no claims or evidence will be accepted after expiration of the deadline.
According to the terms of the Warrant Instrument shareholders who held shares of the Company from 5 October 2017, being the date of readmission of its shares to trading on the main market of the London Stock Exchange ('Admission'), for a period of 60 days ('Qualifying Shareholders') were entitled to apply to receive 1 warrant to subscribe in cash at four pence (Pound 0.04) per share for Ordinary Shares in the capital of the Company for every 2 Ordinary Shares held through the qualifying period to 3 December 2017 (the 'Warrant Issue Date').
Qualifying Shareholders with outstanding claims for warrants are invited to submit completed copies of the Warrant Entitlement Certificate form set out as Schedule 4 of the Warrant Instrument along with evidence of their qualifying holdings on or before Admission and on or after the Warrant Issue Date. Qualifying Shareholders with holdings through nominees are encouraged to request their nominees' assistance in providing evidence supporting claims to warrants. The Company's board of directors has resolved to accept warrant claims from nominees on behalf of Qualifying Shareholders so long as evidence for the entitlement of each individual underlying Qualifying Shareholder is demonstrated to the board's satisfaction.
Copies of the Warrant Instrument, Warrant Entitlement Certificate form to be completed, and guidance on evidence likely to be accepted by the Company's board may be obtained by writing to the Company Secretary, Andrew Wright, by email to firstname.lastname@example.org or by post to the Company's registered office, Hemogenyx Pharmaceuticals plc, 5 Fleet Place, London, EC4M 7RD. Claims should be submitted so that they are received no later than Friday 14 June 2019.
Hemogenyx Pharmaceuticals plc
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
Sir Marc Feldmann, Executive Chairman
SP Angel Corporate Finance LLP
Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Corporate Finance Limited
Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
US Media enquiries
Tel: +1 (323) 646-3249
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc ('Hemogenyx') is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly-owned US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility and a wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL, located in Liège.
Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com: